InnoCare Pharma Limited (OTCMKTS:INCPF) Short Interest Down 50.9% in May

InnoCare Pharma Limited (OTCMKTS:INCPF) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,773,329 shares, a drop of 50.9% from the April 30th total of 5,643,832 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

InnoCare Pharma Stock Performance

Shares of INCPF stock remained flat at $1.55 on Monday. The company has a 50 day moving average of $1.55 and a two-hundred day moving average of $1.83. InnoCare Pharma has a twelve month low of $1.55 and a twelve month high of $2.31.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised InnoCare Pharma to an “overweight” rating in a research note on Thursday. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

InnoCare Pharma Company Profile

InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.

The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.